Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Shares Outstanding (2020 - 2025)

Barinthus Biotherapeutics' Shares Outstanding history spans 6 years, with the latest figure at $40.8 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 1.53% year-over-year to $40.8 million; the TTM value through Dec 2025 reached $40.8 million, up 1.53%, while the annual FY2025 figure was $40.8 million, 1.53% up from the prior year.
  • Shares Outstanding reached $40.8 million in Q4 2025 per BRNS's latest filing, roughly flat from $40.8 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $40.8 million in Q4 2025 to a low of $63443.0 in Q1 2022.
  • Average Shares Outstanding over 5 years is $14.0 million, with a median of $570987.0 recorded in 2021.
  • Peak YoY movement for Shares Outstanding: crashed 92.82% in 2021, then skyrocketed 64252.67% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $63443.0 in 2021, then changed by 0.0% to $63443.0 in 2022, then soared by 60810.64% to $38.6 million in 2023, then grew by 4.12% to $40.2 million in 2024, then rose by 1.53% to $40.8 million in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Shares Outstanding are $40.8 million (Q4 2025), $40.8 million (Q3 2025), and $40.3 million (Q2 2025).